AptarGroup, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to APTAR's 2020 Third Quarter Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Introducing today's conference call is Mr. Matt Della Maria, Senior Vice President, Investor Relations and Communications. Please go ahead, sir.

Thank you and welcome, everyone. Participating on our call today are Stephan Tanda, President and Chief Executive Officer, and Bob Kuhn, Executive Vice President, Chief Financial Officer and Secretary. You can find a copy of our press release as well as a slide presentation file that summarizes our results on our website. If you are following along on our website, you can advance the slides by hovering over the presentation screen and clicking on the arrows on the right and left. We will also post a replay of this conference call on our website. Today's call includes some forward-looking statements. Please refer to our SEC filings to review factors that could cause actual results to differ materially from those projected or contained in the forward-looking statements. APTAR undertakes no obligation to update the forward-looking information contained therein. I would now like to turn the conference call over to Stephan.

Thanks, Matt, and good morning, everyone. I hope that you and your families are continuing to stay healthy and safe during this time. We appreciate you joining us today. We began this pandemic journey early in the year, learning from our Chinese colleagues in late January and standing up a crisis team to oversee the evolving situation with a focus on our people and the production of essential dispensing solutions. Our priorities remain the health and safety of our people and the continuity of production so that we can deliver on our promises and provide the drug delivery and consumer dispensing solutions that are helping millions of people each and every day. I would like to thank our dedicated people around the world who have contributed so much to ensure the supply and support of our customers and end consumers and patients everywhere. As shown on slide three, We continue to adapt our safety procedures and working policies to comply with new insights and local government regulations. Our COVID-19 action team is rigorously monitoring the pandemic and we have maintained a regular cadence of town hall and other communications with our employees. Most of our travel restrictions and the limitations on the number of visitors to our facilities remain firmly in place. Like all of us, we have also rapidly boosted electronic collaboration. To further increase customer engagement and to ensure we share our broad solution expertise, especially during this time, we have greatly increased deployment of digital engagement formats and the training of our people in their effective use. On a daily basis, our segments are holding virtual events, digital co-creation sessions, and webinars with our customers, potential prospects, and industry partners. Our pharma segment has also launched a knowledge hub which contains our latest scientific content and digital event information, all designed to inspire and foster innovation. We are encouraged that, as a result, our new business development and innovation pipelines remain strong across all segments. Now turning to our quarterly financial performance in slide four, I am pleased to report top-line and bottom-line growth, especially when considering the current pandemic conditions. Our diverse product portfolio serves multiple attractive end markets that are each long-term growth markets. Today, we know Two of those markets remain temporarily impacted, while all others are growing nicely. Our recent acquisitions, in particular Fusion PKG and Noble, are also performing well. In addition to the organic core growth over the prior year, we are generating a strong level of cash flow and have exceeded prior year levels through the nine months to date. Moving to slide five, our pharma business, which is the best of breed global leader in drug delivery solutions and services, and has been a very consistent growth franchise for many years, turned in another impressive performance. We grew core sales of our devices and primary components in each end market. However, increased sales of the drug delivery devices were offset by lower custom tooling sales in the prescription market. The 11% core growth for the segment was on top of the very strong quarter a year ago. Current period growth was driven primarily by increased demand for primary components used with injected medicines, such as existing seasonal flu vaccines and other treatments, as well as some beginning orders in anticipation of coming COVID-19 vaccines. Since the onset of the pandemic, we have seen a consistently increasing recognition of our technical capabilities in the injectable field and a steadily rising number of attractive inquirers from pharma and biopharma customers. And we expect that positive trend to continue. During the quarter, we also benefited from increased demand for our consumer healthcare and active packaging solutions. We continue to be optimistic that we will benefit from a global increase in demand for primary components used with injected medicines, including those related to COVID-19 vaccines and therapies, at least to the degree of our market share. Now I would like to share a few recent pharma product and technology launches. Our after pharma services company, Novo, recently launched Adhere IT, a connected, intuitive, and user-friendly onboarding solution for the growing number of patients with chronic conditions who use auto-injectors to administer their medications at home. This is the first fully interchangeable connected add-on solution that can work across a multitude of auto-injector platforms. This launch is an important advancement for patients who self-administer their therapies, and it furthers our mission to provide robust training devices and onboarding programs. In the quarter, we also helped P&G launch their Vicks Cynex saline ultrafine nasal mist in the U.S., featuring our bag-on-vowel system and actuator. Our metering valves for inhalers used to treat asthma and COPD are found on medications in Mexico, Turkey, and South America. Finally, our unidose nasal system can be found on a new naloxone nasal spray called Ventisolve in Sweden that is used to reverse the effects of an opioid overdose. Now turning to slide six and starting with beauty at home, we continue to see strong demand in the personal care market for our dispensing pumps and closures for hand sanitizers and liquid soaps, and increased sales to the home care market primarily related to cleaners and disinfectants. While the beauty market did experience some positive trends in the early part of the quarter due to the reopening of many stores, This market continues to be negatively impacted by the effects of COVID-19 and sales decreased compared to a year ago. We were encouraged by the level of activity related to retail sales, although it is not clear if that level of consumer movement and spending will continue as we head into the winter months in the Northern Hemisphere. Customer engagement and dialogue is at a good level, especially around sampling systems, which we perceive as a positive signal. We also continue to implement cost containment measures and streamline our footprint. Turning to recent global product launches in the quarter, our pumps and closures continue to be featured in numerous sanitizing and cleansing products in the worldwide fight against COVID-19. We helped Unilever launch a new Zest brand of antibacterial spray in Mexico, featuring our spray pump, along with an antibacterial hand soap featuring our closure. Our ocean pump is found on a new antibacterial hand soap for Unilever's Vaseline and Lifebuoy brands in Thailand. In India, we helped Colgate launch a mouth protect spray with our pump. We also supplied several new perfume and cologne launches, including Tribeca by Bond No. 9, Tom Ford by Estee Lauder, Peony Rose by Avon, and many others. Moving now to food and beverage, we reported strong cold growth in the food market that was partially offset by lower sales to the beverage market due to the on-the-go and beverage category being affected by the pandemic. The strong growth in the food market is attributed to the demand for pantry staples with consumers continuing to dine at home more. In addition, the effects of passing through lower resin prices to customers also affected the segment's overall growth. Turning to recent product launches, our closure is found on a new Big Mac sauce for purchase at McDonald's in Brazil, and our closures with SimpliSqueeze Valve are found on the new inverted old El Paso taco sauce and the new oral hygiene water enhancer for pets called Tally Ho by Ocean Spray. Before I turn the call over to Bob, I would like to share a few additional highlights as shown in slide seven. We have recently joined the Gender and Diversity KPI Alliance, a group of D&I advocates and more than 50 corporate leaders to support the use of key performance indicator as high-level internal measurements to provide an overview of the diversity of our workforce. We will use key performance indicators to measure gender and underrepresented groups. We also publicly announced that our science-based targets have been validated by the Science-Based Target Initiative You set an emission reduction goal consistent with requirements to keep global warming well below 2 degrees Celsius by the year 2030. The science-based approach incorporates after its own operations electricity, fuel, oil, natural gas, and refrigerant use, and operations within the value chain, including transportation of goods, raw materials, travel, and commuting. Our business strategy focuses on reducing our environmental impact while living after our purpose and responsibility to society. We remain committed to running and encouraging increasingly energy-efficient operations along the entire value chain. With that, I will now turn it over to Bob, who is going to provide additional comments on our results. Bob?